For instance, Necrostatin-1 and its derivative Nec-1s, both RIPK1 inhibitors, have been shown to attenuate RIPK1-dependent necroptotic signaling, thereby reducing inflammation and tissue injury caused by SARS-CoV-2 infection, as well as mitigating cell death and inflammatory responses in acute lung injury (ALI) [84,85,86,87]. The gene discussed is RIPK1; the disease is acute respiratory distress syndrome.